Medivir — Share Issue/Capital Change 2010

Jun 30, 2010

Press Release, 30 June 2010

Increased number of shares and votes in Medivir

The number of shares and the number of votes in Medivir have changed as a result of the rights issue carried out by the company as well as the exercise of employee stock options.

Today, the last trading day of the month, there are in total 26,222,662 shares and 32,162,662 votes in Medivir.

For additional information, please contact

Rein Piir, CFO & VP Investor Relations, Medivir; Office phone +46 8 54683123 Cell phone +46 708 537 292.

Medivir

Based on its world class expertise in protease and polymerase inhibition technology, Medivir develops drugs with primary focus on infectious diseases. Its objective is to become a sustainable and profitable specialty pharmaceutical company with a strong research base.

Medivir's first pharmaceutical product - for the topical treatment of cold sores - has recently been approved by the US FDA (trademark "Xerese™") and in Europe (trademark "Xerclear™"). The product will be commercialized through partners outside the Nordic region, where Medivir intends to market and sell the product.

For more information on Medivir, please see the company website: www.medivir.se